Orexo has been granted a patent for a nasal applicator device that delivers a composition in the form of an amorphous powder to the nasal mucosa. The composition includes epinephrine as the active ingredient and a combination of a disaccharide and a polymeric material as the carrier. The device is designed to deposit an effective dose of epinephrine to the nasal mucosa upon actuation. GlobalData’s report on Orexo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Orexo, Cancer treatment biomarkers was a key innovation area identified from patents. Orexo's grant share as of September 2023 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Nasal applicator device for delivering epinephrine powder to nasal mucosa
A recently granted patent (Publication Number: US11737980B2) describes a nasal applicator device for intranasal delivery of a composition to the nasal mucosa. The device includes a reservoir containing an amorphous powder composition, which is free of liquid propellant. The amorphous powder consists of epinephrine or a pharmaceutically-acceptable salt as the active ingredient, along with a combination of a disaccharide and a polymeric material as the carrier material. The particles of the amorphous powder are of a size that allows the device to deposit an effective dose of epinephrine to the nasal mucosa upon actuation.
The patent claims also specify various aspects of the nasal applicator device. It is mentioned that the amorphous powder is a dry powder and that the device is a single-use device containing a single dose of the powder. The particles of the amorphous powder have a size distribution with a D10 value above about 10 µm and a D90 value below about 500 µm or below about 100 µm. The carrier material in the composition includes a combination of lactose or trehalose and a maltodextrin. The ratio of disaccharide to polymeric material in the composition is in the range of about 10:1 to about 1:20 or about 2:1 to about 1:8. The composition may also include sucrose monolaurate as a sucrose ester. The pharmacologically-effective dosage amount of epinephrine in the composition is between about 0.1 mg and about 5 mg.
The patent also covers a process for manufacturing the nasal applicator device, which involves loading the amorphous powder into the reservoir of the device. The loaded powder is a dry, amorphous powder.
Overall, this patent describes a nasal applicator device that delivers epinephrine to the nasal mucosa using an amorphous powder composition. The device is designed for single-use and contains a specific combination of carrier materials to ensure effective delivery. The patent also includes details about the particle size distribution, the ratio of ingredients, and the manufacturing process.
To know more about GlobalData’s detailed insights on Orexo, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
